![Mrinal Patnaik: ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact](https://oncodaily.com/pub/uploads/2024/06/mrinal-patnaik.jpg)
Photo of Mrinal Patnaik from mayo.edu
Jun 27, 2024, 02:57
Mrinal Patnaik: ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact
Mrinal Patnaik, Physician Scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota, shared a post on X:
“ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions.”
Source: Mrinal Patnaik/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023